DepYmed

Farmingdale, United States

DepYmed is a disease therapeutic development company that develops potent inhibitors of the enzyme PTP1B.

$1.1M raised

Mar 2024

Venture - Series Unknown

Top Investors

Accelerate New York Seed Fundthe Long Island Emerging technologies Fund (LIETF)Topspin FundAccelerate Long Island

19,000+ verified contacts

Emails, phones & LinkedIn profiles

How much funding has DepYmed raised?

DepYmed has raised $1.1M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in March 2024.

Who are DepYmed's investors?

DepYmed's investors include Accelerate New York Seed Fund, the Long Island Emerging technologies Fund (LIETF), Topspin Fund, Accelerate Long Island.

Where is DepYmed headquartered?

DepYmed is headquartered in Farmingdale, United States.

What does DepYmed do?

DepYmed is a disease therapeutic development company that develops potent inhibitors of the enzyme PTP1B.

What stage is DepYmed at?

DepYmed is at the Venture - Series Unknown stage.

Cite this page

Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated March 11, 2024.

MLA

"DepYmed — Funding & Investors." VCBacked, March 11, 2024, https://www.vcbacked.co/company/depymed. Accessed June 5, 2026.

APA

VCBacked. (2024). DepYmed — Funding & Investors. Retrieved June 5, 2026, from https://www.vcbacked.co/company/depymed

Wikipedia (cite web)

{{cite web |title=DepYmed — Funding & Investors |url=https://www.vcbacked.co/company/depymed |website=VCBacked |access-date=June 5, 2026}}

Profile data sourced and verified per the VCBacked methodology. Last funding round dated March 11, 2024.